SQI snags $4.2M to dial up its marketing push

SQI Diagnostics has raised $4.2 million through a public offering, selling off shares and warrants to bankroll its commercialization plans. The company makes most of its revenue off of companion diagnostics partnerships with drugmakers, but SQI is working toward winning FDA clearance for an in vitro test for celiac disease. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.